ARTICLE | Company News

Momenta, CSL deal

January 12, 2017 10:16 PM UTC

Momenta granted CSL exclusive, worldwide rights to develop and commercialize preclinical autoimmune candidate M230 and other undisclosed Fc multimer proteins. Momenta expects to begin clinical testing of the selective immunomodulator of Fc receptors this year. The companies expect to close the deal this quarter.

Momenta will receive $50 million up front and is eligible for up to $550 million in development and sales milestones associated with the M230 license. Momenta also will be eligible for mid-single-digit to low-double-digit royalties on sales of M230 and an undisclosed research project. The companies will negotiate milestone payments for the undisclosed project as well as royalties and milestone payments for any other products developed under the deal...